{"id":"dacogen-decitabine-only","safety":{"commonSideEffects":[{"rate":"60–90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30–50","effect":"Nausea and vomiting"},{"rate":"30–40","effect":"Fatigue"},{"rate":"20–30","effect":"Constipation"},{"rate":"20–30","effect":"Fever"},{"rate":"20–30","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decitabine is a cytidine analog that inhibits DNA methyltransferase (DNMT), leading to hypomethylation of DNA. In myelodysplastic syndromes and certain leukemias, aberrant DNA methylation silences tumor suppressor genes; decitabine reverses this epigenetic silencing, allowing re-expression of growth-inhibitory genes and promoting cell differentiation and death. This mechanism is distinct from traditional chemotherapy and works through epigenetic modulation rather than direct cytotoxicity.","oneSentence":"Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:33.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndromes (MDS), including previously treated and untreated patients"},{"name":"Acute myeloid leukemia (AML) in elderly patients ineligible for intensive chemotherapy"}]},"trialDetails":[{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06379360","phase":"PHASE2","title":"Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Acute Myeloid Leukemia","enrollment":77},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT06511882","phase":"PHASE2","title":"Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-07","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT06297629","phase":"PHASE2","title":"A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-01","conditions":"Allogeneic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT05403450","phase":"PHASE1","title":"A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-02-22","conditions":"Relapsed/Refractory Peripheral T-cell Lymphoma","enrollment":33},{"nctId":"NCT03445858","phase":"EARLY_PHASE1","title":"Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-02-12","conditions":"Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer","enrollment":22},{"nctId":"NCT06284460","phase":"PHASE1, PHASE2","title":"Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-31","conditions":"Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm","enrollment":""},{"nctId":"NCT04854889","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-04-22","conditions":"Refractory Aplastic Anemia","enrollment":3},{"nctId":"NCT06091267","phase":"PHASE1, PHASE2","title":"PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Beijing Research Institute","startDate":"2023-10-16","conditions":"Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT02961101","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies","status":"RECRUITING","sponsor":"Han weidong","startDate":"2016-05","conditions":"Malignancies Multiple","enrollment":250},{"nctId":"NCT03679650","phase":"PHASE1","title":"Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-10-11","conditions":"Acute Myelogenous Leukemia","enrollment":28},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT06327685","phase":"PHASE1","title":"Avapritinib With Decitabine in Patients With SM-AHN","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-13","conditions":"Systemic Mastocytosis With an Associated Hematologic Neoplasm","enrollment":34},{"nctId":"NCT07318662","phase":"","title":"Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-01-01","conditions":"MDS, CMML","enrollment":224},{"nctId":"NCT05184842","phase":"PHASE2","title":"Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-03-23","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":91},{"nctId":"NCT06291285","phase":"PHASE1","title":"A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-27","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT04245397","phase":"PHASE1","title":"Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2020-06-30","conditions":"Myelodysplastic Syndromes","enrollment":151},{"nctId":"NCT04657081","phase":"PHASE1, PHASE2","title":"Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2021-02-09","conditions":"Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT05918055","phase":"PHASE1, PHASE2","title":"Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-14","conditions":"Myelodysplastic Syndromes","enrollment":3},{"nctId":"NCT03132454","phase":"PHASE1","title":"Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-07-25","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT04878432","phase":"PHASE2","title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-17","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":39},{"nctId":"NCT07014462","phase":"PHASE1","title":"A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML","status":"ENROLLING_BY_INVITATION","sponsor":"University of Vermont","startDate":"2025-09-01","conditions":"AML - Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05148234","phase":"PHASE1, PHASE2","title":"BMS-986253 in Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-29","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT03019003","phase":"PHASE1","title":"Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-03-20","conditions":"Head and Neck Cancer","enrollment":13},{"nctId":"NCT04482621","phase":"PHASE2","title":"Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial","status":"SUSPENDED","sponsor":"Johns Hopkins University","startDate":"2020-09-14","conditions":"COVID-19","enrollment":33},{"nctId":"NCT07117422","phase":"NA","title":"Venetoclax-Decitabine in Untreated Elderly/Unfit AML","status":"RECRUITING","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2025-01-17","conditions":"AML, Adult","enrollment":39},{"nctId":"NCT02269280","phase":"PHASE2","title":"Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-13","conditions":"Leukemia","enrollment":185},{"nctId":"NCT03680677","phase":"","title":"Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2018-09-21","conditions":"Leukemia, Acute, MDS","enrollment":20},{"nctId":"NCT07007767","phase":"PHASE2","title":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-15","conditions":"Colorectal Cancer Metastatic","enrollment":32},{"nctId":"NCT05829226","phase":"PHASE1","title":"A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"PureTech","startDate":"2022-12-12","conditions":"AML, Adult Recurrent, MDS","enrollment":90},{"nctId":"NCT04055818","phase":"PHASE1","title":"A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease","status":"RECRUITING","sponsor":"EpiDestiny, Inc.","startDate":"2020-01-24","conditions":"Sickle Cell Disease","enrollment":20},{"nctId":"NCT05816356","phase":"PHASE1","title":"To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males","status":"COMPLETED","sponsor":"EpiDestiny, Inc.","startDate":"2023-03-24","conditions":"Healthy","enrollment":10},{"nctId":"NCT03066648","phase":"PHASE1","title":"Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-07-06","conditions":"Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute","enrollment":241},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT06686108","phase":"PHASE2","title":"Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-10-30","conditions":"T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse","enrollment":59},{"nctId":"NCT06351306","phase":"PHASE2","title":"DEC-C and Thioguanine for R/R AML","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-04-01","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT02649790","phase":"PHASE1, PHASE2","title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":277},{"nctId":"NCT05190471","phase":"PHASE1","title":"A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Bio-Path Holdings, Inc.","startDate":"2022-08-16","conditions":"Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory","enrollment":48},{"nctId":"NCT06827899","phase":"PHASE2","title":"Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-07-01","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT03092674","phase":"PHASE2, PHASE3","title":"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":76},{"nctId":"NCT04476199","phase":"PHASE2","title":"Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2019-12-09","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT02488408","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2014-10-22","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":122},{"nctId":"NCT06612944","phase":"PHASE2","title":"Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-12","conditions":"Myelodysplastic Syndromes, Adult","enrollment":40},{"nctId":"NCT02281084","phase":"PHASE2","title":"Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-07-06","conditions":"Myelodysplastic Syndromes","enrollment":65},{"nctId":"NCT02664181","phase":"PHASE2","title":"Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2017-06-06","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":13},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02103478","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2014-10-28","conditions":"Myelodysplastic Syndrome, MDS","enrollment":130},{"nctId":"NCT05841771","phase":"PHASE2","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-01-01","conditions":"Hypomethylating Agent, Venetoclax, Myeloid Malignancy","enrollment":78},{"nctId":"NCT04155580","phase":"PHASE1","title":"A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2020-06-12","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT04113616","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-09-25","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)","enrollment":70},{"nctId":"NCT06046313","phase":"PHASE2","title":"Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-10-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":120},{"nctId":"NCT06285136","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Kunming Medical University","startDate":"2024-03-01","conditions":"Acute Myeloid Leukemia, Adult","enrollment":40},{"nctId":"NCT01812252","phase":"PHASE2","title":"Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-08-19","conditions":"Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT05983276","phase":"PHASE2","title":"Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer","status":"RECRUITING","sponsor":"Loyola University","startDate":"2023-11-16","conditions":"Ovarian Cancer","enrollment":40},{"nctId":"NCT02608268","phase":"PHASE1, PHASE2","title":"Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-23","conditions":"Advanced Malignancies","enrollment":252},{"nctId":"NCT03593915","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-08-29","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":20},{"nctId":"NCT03377725","phase":"PHASE3","title":"Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)","status":"WITHDRAWN","sponsor":"Li Junmin","startDate":"2018-03-20","conditions":"Myelodysplastic Syndromes, P53 Mutation","enrollment":""},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT00941109","phase":"PHASE1","title":"Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-12","conditions":"Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT05805072","phase":"NA","title":"Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-05-01","conditions":"Relapsed/Refractory AML","enrollment":20},{"nctId":"NCT03941964","phase":"PHASE3","title":"A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-08-15","conditions":"Acute Myeloid Leukemia (AML), Cancer","enrollment":60},{"nctId":"NCT01177540","phase":"PHASE2","title":"Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2011-03-03","conditions":"Pediatric Acute Myelogenous Leukemia (AML)","enrollment":25},{"nctId":"NCT03063203","phase":"PHASE2","title":"Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2017-07-14","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":17},{"nctId":"NCT03217838","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-07-31","conditions":"Acute Myeloid Leukaemia","enrollment":50},{"nctId":"NCT05282719","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasms, Adult","enrollment":33},{"nctId":"NCT05265962","phase":"PHASE2","title":"Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-12-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":85},{"nctId":"NCT05258799","phase":"NA","title":"Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2022-01-21","conditions":"Acute Myeloid Leukemia","enrollment":130},{"nctId":"NCT02214407","phase":"PHASE3","title":"Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2014-10-14","conditions":"MDS","enrollment":170},{"nctId":"NCT04252248","phase":"PHASE1","title":"Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage","status":"TERMINATED","sponsor":"University Hospital Heidelberg","startDate":"2019-10-11","conditions":"Head and Neck Cancer, Anogenital Cancer","enrollment":3},{"nctId":"NCT03113071","phase":"PHASE1, PHASE2","title":"Safety and Activity of Digoxin With Decitabine in Adult AML and MDS","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2017-06-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":1},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04582604","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Decitabine for High Risk Hematological Malignancies","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":60},{"nctId":"NCT04373395","phase":"NA","title":"Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2020-01-01","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT04515914","phase":"","title":"Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-09","conditions":"Myelodysplastic Syndrome","enrollment":68},{"nctId":"NCT04233294","phase":"PHASE2","title":"Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-02-02","conditions":"Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia","enrollment":100},{"nctId":"NCT04279379","phase":"PHASE2","title":"Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-04-01","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":20},{"nctId":"NCT04353479","phase":"PHASE2","title":"Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-04-25","conditions":"Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT02252107","phase":"PHASE2","title":"10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":46},{"nctId":"NCT01546038","phase":"PHASE2","title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06-27","conditions":"Acute Myeloid Leukemia","enrollment":255},{"nctId":"NCT04086238","phase":"PHASE1","title":"Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects","status":"COMPLETED","sponsor":"EpiDestiny, Inc.","startDate":"2019-10-08","conditions":"Healthy","enrollment":46},{"nctId":"NCT02954653","phase":"PHASE1","title":"A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-11-28","conditions":"Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT00260832","phase":"PHASE3","title":"Trial of Decitabine in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-11","conditions":"Acute Myeloid Leukemia","enrollment":485},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50},{"nctId":"NCT03395873","phase":"PHASE1","title":"Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2018-01-29","conditions":"Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT04049344","phase":"PHASE2","title":"Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-15","conditions":"Metastatic Renal Cell Carcinoma","enrollment":25},{"nctId":"NCT03913312","phase":"PHASE1, PHASE2","title":"Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-09-01","conditions":"Acute Myeloid Leukemia","enrollment":150},{"nctId":"NCT03828084","phase":"PHASE1","title":"Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"EpiDestiny, Inc.","startDate":"2019-04-03","conditions":"Healthy","enrollment":16},{"nctId":"NCT03250962","phase":"PHASE2","title":"SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-09-11","conditions":"Hodgkin Lymphoma","enrollment":280},{"nctId":"NCT02472145","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-04","conditions":"Leukemia, Myeloid, Acute","enrollment":326},{"nctId":"NCT02076191","phase":"PHASE1, PHASE2","title":"Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML","status":"COMPLETED","sponsor":"John Mascarenhas","startDate":"2014-02","conditions":"Myeloproliferative Neoplasms","enrollment":49},{"nctId":"NCT01876641","phase":"PHASE1","title":"Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib","status":"TERMINATED","sponsor":"Mohammed M Milhem","startDate":"2013-10","conditions":"Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma","enrollment":18},{"nctId":"NCT03252457","phase":"PHASE3","title":"Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-09-01","conditions":"Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia","enrollment":200},{"nctId":"NCT03356080","phase":"PHASE2","title":"DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2017-07-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":732,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["decitabine"],"phase":"phase_3","status":"active","brandName":"Dacogen (decitabine) only","genericName":"Dacogen (decitabine) only","companyName":"Eisai Inc.","companyId":"eisai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Decitabine is a DNA methyltransferase inhibitor that reduces DNA methylation, reactivating silenced tumor suppressor genes and promoting differentiation and apoptosis in myelodysplastic cells. Used for Myelodysplastic syndromes (MDS), including previously treated and untreated patients, Acute myeloid leukemia (AML) in elderly patients ineligible for intensive chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}